Selective muscarinic receptor agonists and antagonists.
Article Details
- CitationCopy to clipboard
Eglen RM, Watson N
Selective muscarinic receptor agonists and antagonists.
Pharmacol Toxicol. 1996 Feb;78(2):59-68.
- PubMed ID
- 8822036 [ View in PubMed]
- Abstract
Muscarinic receptors are composed of a family of four subtypes each of which can be distinguished pharmacologically and structurally. The physiological role of each subtype in the central and peripheral nervous systems remains to be clarified, due, in part, to a lack of agonists and antagonists with adequate subtype selectivity. Nonetheless, several agonists with functional selectivity for M1 receptors are now in advanced clinical evaluation for Alzheimer's disease, while selective M1/M3 antagonists may prove useful in the treatment of disorders of smooth muscle function. These novel compounds thus provide an advance over earlier therapeutics with which the clinical efficacy was compromised by the side effect profile. This review attempts to assess novel, selective agonists and antagonists, both in terms of their use in defining muscarinic receptor subtypes and their potential clinical utility.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Trimebutine Muscarinic acetylcholine receptor M1 Protein Humans YesAntagonistDetails Trimebutine Muscarinic acetylcholine receptor M2 Protein Humans YesAntagonistDetails Trimebutine Muscarinic acetylcholine receptor M3 Protein Humans YesAntagonistDetails Trimebutine Muscarinic acetylcholine receptor M4 Protein Humans YesAntagonistDetails